Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 21;16(1):181.
doi: 10.1186/s12883-016-0705-1.

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy

Uwe Klaus Zettl  1 , Ulrike Bauer-Steinhusen  2 , Thomas Glaser  2 , Klaus Hechenbichler  3 , Michael Hecker  4 ; Study Group
Affiliations

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy

Uwe Klaus Zettl et al. BMC Neurol. .

Abstract

Background: Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients' perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care professionals and the relationship to the treating physician.

Methods: In this report, we considered physicians' and patients' evaluation of satisfaction with interferon beta-1b treatment efficacy for assessing the congruence in ratings. Data were queried in a study conducted between 2009 and 2013.

Results: After 6 months of therapy, > 80 % of the patients and physicians (N = 445) showed high degrees of satisfaction regarding interferon beta-1b treatment, with only few physicians and patients (≤2.0 %) rating "not satisfied". The proportion of patients rating with the same category as their physicians was similar after 6 months (47 % congruence) and at the 24 months/study end visit (49 %). Discrepancies between ratings were observed with respect to study end: for patients with premature study end, more patients and physicians rated being not satisfied with the therapy, accompanied by a considerably lower congruence of 33 % compared to 54 % for patients receiving the therapy for at least 2 years and completing the study regularly.

Conclusions: Regular communication between physicians and patients about their perception of therapy might improve alignment of treatment evaluation and could result in increased therapy persistence. In addition, patients' willingness to perform a long-term therapy - even in the absence of disease symptoms - might be promoted by repeated exchange between health care providers and patients with regard to realistic treatment expectations.

Trial registration: ClinicalTrials.gov NCT00902135 (registered May 13, 2009).

Keywords: Interferon beta-1b; Multiple Sclerosis; Patient-Physician Relationship; Therapy Adherence; Treatment Satisfaction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Satisfaction with interferon beta-1b therapy. a Physicians' and patients’ ratings of the therapy 6 months after the start of treatment as documented by the physicians in case report forms (CRF) and by the patients in a separate questionnaire. b Physicians' and patients’ ratings of the therapy at the final visit (24 months/study end), with substratification for patients with regular or premature study termination. pat. = patients; phys. = physicians; quest. = questionnaire
Fig. 2
Fig. 2
Congruence of physicians’ and patients’ evaluation of the therapy. Comparison of physicians’ and patients’ ratings of the interferon beta-1b therapy for multiple sclerosis (a) at the 6 months visit and (b) at the 24 months visit/study end, substratified for (c) regular and (d) premature study termination. CRF = case report forms; shaded areas = proportion of congruent ratings of patients and physicians
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72:132–41. doi: 10.1159/000360528. - DOI - PubMed
    1. Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. 2014;3:294–302. doi: 10.1016/j.msard.2013.11.005. - DOI - PubMed
    1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225–40. doi: 10.1016/j.mayocp.2013.11.002. - DOI - PubMed
    1. Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71:S21–3. doi: 10.1212/WNL.0b013e31818f3dcb. - DOI - PubMed
    1. Visser LH, van der Zande A. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. Eur J Neurol. 2011;18:1343–9. doi: 10.1111/j.1468-1331.2011.03411.x. - DOI - PubMed

Associated data

LinkOut - more resources